<DOC>
	<DOCNO>NCT01437241</DOCNO>
	<brief_summary>The purpose study evaluate virological clinical efficacy etravirine plus 2 active nucleos ( ) ide reverse-transcriptase inhibitor ( NRTIs ) HIV-infected patient . Additionally , safety regimen , specially lipid profile , assess .</brief_summary>
	<brief_title>Etravirine Plus 2 Analogs HIV-infected Patients</brief_title>
	<detailed_description>Methods : prospective , single arm multicenter clinical trial without entry restriction plasma HIV-RNA ( VL ) CD4 plan duration 52 week . The primary clinical endpoint percentage subject therapeutic success etravirine 400 mg/day ( 200 mg bid 400 mg qd ) plus 2 active NRTIs 12 month . Efficacy data analyze on-treatment intention-to-treat analysis ( noncomplete/missing equal failure ) , consider treatment failure either treatment interruption whatever reason ( adverse event , death , loss follow-up ) virological failure , define inability suppress VL le 50 copies/ml 24 week treatment confirm VL 200 copies/ml patient previously achieve viral suppression undetectable viral load inclusion . Patients miss two consecutive schedule visit consider lose follow-up . The safety tolerability study medication evaluate mean clinical adverse event , physical examination laboratory result . NRTIs prescribe part HAART select responsible physician basis previous antiretroviral treatment and/or genotypic resistance testing .</detailed_description>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Older 18 year , start antiretroviral regimen base etravirine plus 2 NRTIs January 2009 June 2010 , evidence activity drug basis treatment history genotypic resistance testing , informed consent , least one followup visit . Genotypic resistance test evidence resistance drug use , concomitant use drug potentially adverse interaction etravirine pharmacokinetics , rifampin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>HIV-infection</keyword>
	<keyword>Etravirine</keyword>
	<keyword>Treatment</keyword>
	<keyword>Non-nucleoside reverse-transcriptase inhibitor</keyword>
</DOC>